A recent study contradicts the widely held medical approach of lowering opioid doses during pregnancy to avoid severe neonatal opioid withdrawal syndrome (NOWS). The research determined that reducing medication does not alleviate withdrawal symptoms in newborns and instead exposes mothers to greater risks. The findings were published in JAMA Network Open on October 29, where investigators examined whether doses of methadone and buprenorphine—the two medications commonly used to treat opioid use disorder during pregnancy—were associated with the severity of the withdrawal syndrome in newborns. They analyzed medication concentrations in umbilical cord tissue, which reflects fetal exposure during the final trimester. Surprisingly, higher medication levels did not correspond with more severe withdrawal in infants.
Methadone vs. buprenorphine: withdrawal risks differ
Severe withdrawal, characterized by symptoms such as seizures, vomiting, fever, or hypothermia, occurred in approximately 44 percent of the newborns included in the study. While infants exposed to methadone showed higher severe withdrawal rates compared to those exposed to buprenorphine, the mother’s medication dose did not influence symptom severity. Additionally, cord tissue concentrations revealed no meaningful difference between infants with severe and less severe withdrawal.
The researchers measured both medications and their metabolites in the umbilical cord tissue, which provides the most objective measure of fetal drug exposure over the final trimester. These results imply that medication exposure alone does not dictate withdrawal severity, suggesting other variables, such as placental function, fetal development, or individual newborn responses, may play a greater role. The study directly challenges the prevailing belief that reducing doses protects infants from withdrawal.
Courtney Townsel, MD, MS, the lead author and an Associate Professor of Obstetrics, Gynecology and Reproductive Sciences at the University of Maryland School of Medicine, emphasized that the study’s conclusions refute common fears. The findings suggest that lowering medication doses during pregnancy is not an effective strategy for preventing severe neonatal opioid withdrawal syndrome (NOWS) and reinforce the importance of maintaining treatment to protect mothers from relapse and overdose. The research shows that dose reduction strategies may inadvertently harm maternal health without improving neonatal outcomes. Townsel noted that the study’s findings directly address concerns about medication safety in pregnancy, reinforcing that the fear of worsening withdrawal in newborns is not supported by evidence.
Related Post: Poor Metabolic Health Raises Chronic Disease Risk
Opioid deaths rise, why dose cuts backfire
Opioid use disorder is a leading cause of death associated with pregnancy and the postpartum period, according to the American Medical Association. Mortality rates rose more than 80 percent between 2017 and 2020. Medication for opioid use disorder (MOUD) is an evidence-based treatment that helps stabilize the condition and reduce the risk of relapse and overdose, and has been shown to be safe in general to use during pregnancy.
The study’s findings suggest that such caution may be misplaced, as dose reduction does not mitigate withdrawal severity and instead compromises maternal safety. The researchers show that maintaining effective treatment is key for preventing relapse and overdose, which are significant risks for pregnant patients.
The study acknowledges limitations, including a small sample size of 92 pregnancies and insufficient racial and ethnic diversity, which may restrict the generalizability of the results. Nevertheless, the research reinforces the need for treatment approaches that prioritize maternal health while ensuring newborns receive appropriate monitoring and care for withdrawal symptoms. Clinicians are encouraged to maintain effective medication levels rather than reducing doses, balancing the need to stabilize pregnant patients against the risks of relapse or overdose. The findings support individualized treatment plans that focus on maternal stability without unnecessary dose adjustments.